Unlock your lab’s full potential with CrossLab Asset Monitoring

Managing the business of a lab is a whole other science and it’s time-consuming. Controlling costs, and budget and making sure the laboratory meets its business growth goals is a challenge.

The operational data you collect from your instruments is a valuable tool for improving many areas of performance. However, manually collecting sets of data and relying on paper-based aggregation will not give you a complete understanding of your lab efficiency and productivity.

Agilent CrossLab Asset Monitoring capabilities pull together advanced Internet of Things (IoT) sensor technology and data analytics to enable lab-wide visibility. In this webinar, discover how to recognise the hidden costs of not collecting instrument usage data. It will also explore how to use lab-wide instrument data to make capital expense decisions, reduce operational expenses, and improve productivity. An important point of discussion will be how internet-of-things (IoT) technology is available today to help lab managers measure instrument usage. This webinar is ideal for Lab Operations Managers, Operations Directors or persons in Head of Operations roles.

 

Speakers

Tim Baxter
Marketing Manager
CrossLab Connect Asset Monitoring
Agilent Technologies

 

Michael Farrell
Project Manager, Data Visualization and Insights
Agilent Technologies

 

Moderator

Laura Bush
Editorial Director
LCGC

 

Register and watch on demand >

 

Sustainability Through Lab Optimisation

The average lab consumes more energy per square meter than many hospitals or other commercial buildings—the US EPA estimates that a 30% reduction in lab energy use in the United States translates to removing 1.3 million cars from highways per year. Now, imagine what that would mean for labs around the world.

Scientific labs are experiencing an increasing demand for greater efficiency and productivity and, at the same time, a strong desire to maximise sustainability from the organisation-wide level to daily operations. Combining new data intelligence technologies and better industry insight guidance allows for advancing lab operational efficiency through better asset utilisation and increased sustainability in the digital lab era.

 

Lab managers want sustainability and optimisation

The central premise for discussing sustainability and optimisation together is that a more efficient lab is a more sustainable one. Most lab managers are mindful of both sustainability and optimisation needs. A global survey of lab managers highlighted a strong desire to meet sustainability goals and remain conscious of sustainability in their daily operations.

Key takeaways from the survey included:

  • 68% of labs surveyed acknowledged that they require further work to improve sustainability.
  • The most common sustainability expectations from instrument vendors are to reduce emissions and energy consumption. 68% of the respondents expected instrument vendors to help them reduce emissions, while 58% expected a reduction in energy.
  • Increased efficiency and optimisation are also factors, with the most critical concern being speed as demand for higher sample throughput increases dramatically. The importance that lab leaders place on improving speed, optimisation, and efficiency was also highlighted in a pharmaceutical lab leaders survey.
  • Of those surveyed, 83% believed their workflows needed optimisation, and 63% would welcome innovations to increase efficiency.

 

Advanced asset control, digital analytics, and expert guidance

The opportunity for lab optimisation improvement is profound. On average, lab instruments are running only 35% of the time, and only 4% of labs employ data intelligence to ascertain fleet utilisation.

James Connelly, chief executive officer of My Green Lab agrees, “Lab equipment makes up a significant portion of the total plug load in any lab and can lead to high energy consumption. Optimisation of lab equipment through solutions such as asset performance management can dramatically lower the overall energy consumption and be a significant step toward achieving lab sustainability.”

A holistic method of assuring lab-wide optimisation and efficiency is required to address this gap effectively. A combination of advanced asset control, digital analytics, and expert guidance allows greater visibility and utilisation of all lab assets. Maximising the availability and utilisation of all assets will reduce a lab’s carbon footprint and enable more science to be done. Increasing operational efficiency and productivity positively impacts lab sustainability. Reducing energy consumption through increased efficiency is a win-win, especially for the environment.

Data intelligence systems with real-time sensing technology and interconnectivity provide better visibility into lab operations and help drive decisions. Gaining clarity on asset utilisation enables more informed decision-making that advances lab operations to new levels of efficiency and productivity—while increasing sustainability at the same time. Measuring asset utilisation opens the door to appropriate fleet right-sizing and technology refresh, resulting in higher throughput, less power consumption, a smaller workflow footprint, and redeployment of under-used or redundant instruments.

 

Connected labs reduce waste and increase productivity

Labs that are connected benefit from multiple efficiencies that bolster sustainability. Technologies such as smart alerts foster a proactive approach to instrument monitoring. Rather than reacting to an instrument breakdown, an interconnected lab with smart alert software will prevent it from happening in the first place. Interconnectivity also enables the ability to make data-driven decisions.

Interconnective technology can also increase instrument utilisation because it calculates how much science any particular instrument performs per square meter. Sustainability isn’t limited to the traditional ‘green’ metrics of waste and water— it is equally achieved through technology.

For example, having visibility of all instruments at once to produce an overall lab footprint from which adjustments can be made to make the lab more effective and efficient. Or not having to waste time performing duplicate runs because the smart alert system fires when the first doesn’t go through.

 

Go greener with asset monitoring

The process of lab optimisation involves integrating utilisation data with instrument service histories and end-of-guaranteed support to measure the instrument’s health. Understanding instrument utilisation and health can determine the optimal footprint and workflow composition.

A central operations strategy provides lab managers with profound insight into asset composition and health and the means to make data-driven decisions and optimise lab operations. The subsequent improvement of lab-wide efficiency not only increases the productivity of the laboratory as a whole but also lab sustainability by doing more science with less energy and resources. A win for both science and the environment.

 

This article is modified from content originally published by Agilent

 

Avoiding Common Time Traps in ICP-MS Analysis: A Virtual Workshop

Inductively coupled plasma–mass spectrometry (ICP-MS) is a fast, multielement technique used for trace elemental analysis.

But labs that use ICP-MS – or are thinking of installing one – can find it difficult to unlock the true potential of the technique. Unproductive and often unnecessary activities can eat into lab time, reducing productivity, increasing stress, and potentially impacting data quality. Open to all; this workshop will provide insights you can employ to improve efficiency in your laboratory while also reducing pressure on staff and increasing confidence in the results you report.

 

Speakers

Bert Woods
Application Scientist
Agilent Technologies, Inc.

Joined the Agilent ICP-MS team in 2004, with previous employment in the semiconductor industry with Dominion Semiconductor (IBM/Toshiba) and Micron. Bert is a 1997 Chemistry graduate of Radford University in Virginia and an avid Washington DC Sports fan.

 

L. Craig Jones
ICP-MS Application Scientist
Agilent Technologies, Inc.

Craig has been with Agilent for over 15 years as an ICP-MS applications scientist. He has been involved with multiple types of applications for ICP-MS, including environmental, pharmaceutical, nutraceutical, semiconductor, geologic, and clinical analyses, to name a few. Previous to Agilent, he worked in an environmental lab performing analysis and supervising both the inorganic and organic sections of the laboratory. In his spare time, Craig enjoys volunteering at the local marine science centre, mountain biking, hiking and relaxing at the beach. Craig obtained a bachelor of science degree in chemistry from Fort Lewis College in Durango, CO.

 

Register and watch on demand >

 

The Efficiency and Cost Benefits of an Innovative UV-Vis Spectrophotometer

UV-Vis spectroscopy is a mature technology used to analyse, characterise, and quantify pharmaceutical and biological samples such as active pharmaceutical ingredients, DNA/RNA, and proteins for many decades. The use of UV-Vis has been limited by the workflow needed to make these measurements efficiently. The recent advances in UV-Vis spectroscopy focus on enhancing laboratory productivity, offering ease of use, and providing multiple accessories designed specifically for application needs.

Pharmaceutical and biopharmaceutical materials have become more sophisticated in life science research across fields (such as cancer research, drug development, vaccines, and quality control in regulated environments). The technology used for the analysis should evolve, too.

This webinar will highlight the benefit of the new Agilent Cary 3500 Flexible UV-Vis spectrophotometer and its capabilities in improving workflows in the pharmaceutical industry.

 

Speaker

Geethika Weragoda
Application Scientist
Agilent Technologies, Australia

 

Register and watch on demand >

 

Fueling Precision Medicine: From Sequence to Therapeutics

We are on the precipice of the next major shift in science as it relates to medicine. The 20th Century saw an explosion of technological advances that reshaped modern life completely. Today, the surge of discoveries and development continues particularly in biology. It is very possible that our counter arts in the future may look back on the 21st century as the Century of Biology.

 

A look at precision medicine

Precision medicine is the ability to understand and treat disease at a molecular level and it is driving revolutionary change in fields such as oncology. It aims to improve therapeutic outcomes by adding a previously missing but critical factor – the unique biology of the patient being incorporated into the treatment equation. This is done by including DNA sequence information.

According to the U.S. Food and Drug Administration, “Precision medicine, sometimes known as “personalised medicine” is an innovative approach to tailoring disease prevention and treatment that takes into account differences in people’s genes, environments, and lifestyles. The goal of precision medicine is to target the right treatments to the right patients at the right time.”

Based on this foundation, one megatrend to keep an eye on is cellular manufacturing. This is the ability to reprogram cells for practical purposes and it is transforming industrial biotechnology. Many chemicals and materials traditionally produced through petrochemical processes are now the products of engineered biological cells. Cellular manufacturing also requires a deep understanding of cellular metabolism and pathway interdependencies which are being accelerated by the vast amount of metabolomic information becoming available through advancements in mass spectrometry.

Although mass spectrometry is not new, its application in the clinical realm is fairly recent by medical research standards. For over half a century, diagnostics relied on immunoassays but mass spectrometry is addressing many of the limitations of immunoassays and also becoming vitally important to precision medicine. The high accuracy and sensitivity of mass spectrometric analysis of proteomes are suited for the incorporation of proteomics into precision medicine. Mass spectrometry can provide an understanding of how a patient reacts and interacts with a drug. With new instruments now able to easily fit on a benchtop and deliver results accurately at remarkable speeds with lower costs, it’s become the perfect test for precision medicine patient management.

 

A key example of megatrend impact: Cardiovascular disease

Inroads are being made in the treatment of cardiovascular disease through sequencing of the PCSK9 gene where it was discovered that various mutations of this gene are associated with high low-density lipoproteins (LDL) cholesterol levels a factor in multiple diseases. The knowledge that this gene plays a role—that high LDL levels weren’t simply a matter of poor diet—has contributed to the development of inclisiran, a small or short interfering RNA (siRNA) therapeutic that acts to silence the PCSK9 gene and effect clinically significant reductions in LDL cholesterol levels. Sequencing and mass spectrometry are essential to identify which patients have mutations in the PCSK9 gene to identify candidates for inclisiran therapy.

 

The future: Predicting biology

The megatrends of precision medicine and cellular manufacturing share a common driver: the past 20 years have seen a marked shift in our ability to understand and characterise biology as a primarily qualitative science to one that is increasingly quantitative. This shift carries the promise of eventually allowing us to understand, model and predict biology in the same way that we are able to do in the physical sciences—an exceptionally complex proposition that lies beyond our current capabilities. At a fundamental level, as our capacity to understand and control biology at the molecular level deepens our understanding of disease fuels parallel advances in industrial biotechnology.

This article was originally published by Agilent and has been amended here.

 

Analysis of Permanent Gases: More Challenging Than You Might Think

Permanent gases such as carbon monoxide, CO2, O2, N2, and methane are common in refinery gases, natural gas, fuel cell gases, and many other industrial processes. Permanent gas analysis finds wide application in the fields of petrochemical, chemical, and energy industries.

On the surface, this would appear to be a simple separation—however, there are several challenges related to the analysis of permanent gases. This webinar will discuss typical techniques for resolving and detecting permanent gases, including carbon dioxide and hydrogen. Other topics will include cryogenic techniques, column isolation, and the use of the Agilent J&W Select Permanent Gases/CO2 GC column.

 

Speaker

Mark Sinnott
Application Engineer
Agilent Technologies, Inc.

Mark Sinnott works for Agilent Technologies as a Technical Support Engineer in the Consumables and Supplies Division (CSD). In his position at Agilent, Mark performs technical support and applications assistance to gas chromatographers worldwide. He has more than 22 years of experience in gas chromatography, including environmental analysis of compounds in air, soil and water matrices, including dissolved gas analysis for the electrical industry. Mark holds a Master’s Degree in Chemistry from California State University, Sacramento, and currently resides in Twin Falls Idaho.

 

Register and watch on demand >

 

Addressing Data Integrity Gaps: Does Your Lab Have a Strategy?

Data integrity is paramount in today’s digital world. Data Integrity Insights helps your lab stand up to any regulatory examination by informing you about the latest global enforcement trends and the strategies you can use to stay compliant. Presenting uncompromised results and maintaining compliance with the latest regulations and standards, including those issued by the pharmaceutical, environmental and food regulatory bodies, is a necessity.

The traditional approaches to laboratory data integrity are insufficient to meet today’s increased scrutiny of computerised systems and the terabytes of data they produce. To successfully present your results, you must be prepared to prove that your data have not been compromised—and that can be a challenge.

Does your lab have a data integrity strategy? Are data integrity gaps putting your company at risk?

Learn how to perform data process mapping on a chromatographic process from the set-up of analysis through calculating the reportable result. From this map, the data integrity gaps can be identified, and the risk assessed to determine how critical the gaps are so that a plan and strategy to remediate or remove the risks can be implemented.

 

What you will learn

  • Understand the scope of a data integrity program
  • How to perform data process mapping on a chromatographic process to identify data integrity gaps, assess the risk posed by those gaps, and determine how to remediate or solve them.
  • Understand options for short-term remediation and long-term solutions

 

Who should attend

Analytical chemists, technicians, laboratory managers, regulatory affairs personnel and others working in R&D and QA/QC in the pharmaceutical industry.

 

Bob McDowall
Director, RD McDowall
Limited, Bromley,
Kent, UK

Register and watch on demand >

 

Industrialising High-Throughput Glycoproteomics Using AI for Clinical Use

Cancer is a leading cause of death worldwide and there is a great movement globally to develop new treatments and advance how cancer is diagnosed. Technology has been a great help, particularly in recent years, and now there’s new innovation that could take our cancer diagnosis and treatment to a new level.

According to an article published by The Guardian, doctors, scientists and researchers have built an artificial intelligence model that can accurately identify cancer in a development they say could speed up diagnosis of the disease and fast-track patients to treatment. This is but one of many new developments that include AI technology in cancer diagnosis as well as treatment.

In this webinar, we learn the predictive powers of artificial intelligence combined with cutting-edge mass spectrometry to discover clinically relevant biomarkers that can only be revealed by high-resolution analysis of the glycoproteome. This presentation is for all who are interested to learn more about the real-world clinical application of glycoproteomics on cancer diagnosis.

 

Speaker

Dr. Low Ley Hian
Director of Development
InterVenn Biosciences

 

Register and watch on demand >

 

Gather Assay Materials

Energy metabolism drives cell function in health and disease. The landscape of therapeutic discovery is rapidly evolving, and cellular metabolism has emerged as the critical driver of a range of common diseases. Cell biology functions as a network of signaling, pathways, and checkpoints — with cellular metabolism as a central orchestrator to fuel many cellular processes.

The development of safe and effective drugs requires an understanding of genes, proteins, and pathways that may be key intermediates and potential candidates for drug target intervention. Cellular processes are dynamic, and metabolic programs are the upstream determinants of cellular outcomes. Identification and validation of potential drug targets requires a comprehensive view of those upstream drivers to modulate cell response and safely and effectively intervene.

Agilent Seahorse XF technology provides functional, live-cell metabolic measurements for a more direct measure and a deeper understanding of cellular processes. In this training webinar, you will learn about the fundamentals of Agilent Seahorse XF technology, the typical XF assay workflow, the Agilent XF Assay Learning Center resource, and the required and recommended materials to perform a successful XF assay.

 

Register and watch on demand >

 

Join us at analytica Lab Africa 2023

analytica Lab Africa is the premier trade fair for the analysis, laboratory-technology and biotechnology sectors, bringing together scientists, entrepreneurs and users from around the world. Welcome to the perfect platform for your international business relations.

Chemetrix will be taking part in this prestigious event to showcase some of our latest instruments, innovations and partnerships.

 

Why you should visit

The international trade fair analytica Lab Africa focuses on innovative and applied product and system solutions for laboratories in the industrial, research and science sectors. As the industry’s regional forum for Southern Africa, analytica Lab Africa combines global and local market leaders and innovations with country specific main themes, precisely tailored to the market.

 

A global network

analytica gives you access to the world’s largest network of trade fairs for laboratory technology, analysis and biotechnology. Open the door to global success for your company. Present your products and solutions to the markets of the future.Germany, China, India, South Africa and Vietnam.

 

Exciting innovations

Get new and deeper insights into the Agilent product and solution portfolio with Agilent InterAct! Experience your favourite Agilent system in a virtual 3D environment. Visit our stand at the event for the exclusive launch of an immersive experience like never before.

 

Event details

Gallagher Convention Centre is one of Africa’s largest conference and exhibition venues. Located in Midrand, between Pretoria and Johannesburg, Gallagher is conveniently positioned in the business hub of Gauteng.

 

Show Dates

5-7 July, 2023

Venue

Gallagher Convention Center, Johannesburg, South Africa

Opening Hours

Wednesday, 5th July, 0900 hrs – 1700 hrs

Thursday, 6th July, 0900 hrs – 1700 hrs

Friday, 7th July, 0900 hrs – 1600 hrs

 

Register to attend the event >

 

We look forward to connecting with you an analytical Lab Africa 2023